Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1997-2-19
|
pubmed:abstractText |
A double-blind randomized trial was conducted to research a hypercoagulable state rebound after abrupt versus gradual withdrawal of acenocoumarol, 20 patients were included: 10 in the abrupt withdrawal group (AW) and 10 in the gradual withdrawal group (GW). Between days 1 and 15,F1 + 2 was higher in group AW (P < 0.002). A significant increase of D-dimer with time was found (P < 0.001) without difference between the two groups, tPA and PAI-1 levels remained stable throughout without difference between the two groups. No rebound phenomenon was observed. Four thrombotic recurrences were observed: group AW: 1, group GW: 3 (P = 0.29). There is neither clinical nor biological support for a gradual anticoagulation withdrawal.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0007-1048
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
96
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
174-8
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9012705-Acenocoumarol,
pubmed-meshheading:9012705-Blood Coagulation,
pubmed-meshheading:9012705-Double-Blind Method,
pubmed-meshheading:9012705-Female,
pubmed-meshheading:9012705-Fibrinolysis,
pubmed-meshheading:9012705-Humans,
pubmed-meshheading:9012705-Male,
pubmed-meshheading:9012705-Recurrence,
pubmed-meshheading:9012705-Thromboembolism,
pubmed-meshheading:9012705-Time Factors
|
pubmed:year |
1997
|
pubmed:articleTitle |
Evolution of blood coagulation and fibrinolysis parameters after abrupt versus gradual withdrawal of acenocoumarol in patients with venous thromboembolism: a double-blind randomized study.
|
pubmed:affiliation |
Department of Intensive Care, C.H.R.U., Saint-Etienne, France.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|